Vera Therapeutics (VERA) Income from Non-Controlling Interests (2021 - 2023)

Vera Therapeutics (VERA) has 3 years of Income from Non-Controlling Interests data on file, last reported at $29.8 million in Q1 2023.

• Quarterly Income from Non-Controlling Interests rose 74.59% year-over-year to $29.8 million in Q1 2023, while the trailing twelve-month figure through Mar 2023 was $136.2 million (up 524.57% YoY) and the FY2022 annual result came in at $89.3 million, changed N/A from the prior year.
• Income from Non-Controlling Interests slipped to $29.8 million in Q1 2023, from $146.2 million in the prior quarter.
• In the past five years, Income from Non-Controlling Interests ranged from a high of $146.2 million in Q4 2022 to a low of -$24.8 million in Q3 2022.
• A 3-year average of $18.1 million and a median of $4.7 million in 2021 frame the typical range for Income from Non-Controlling Interests.
• The widest YoY moves for Income from Non-Controlling Interests: up 827.4% in 2022, down 336.22% in 2022.
• Tracing VERA's Income from Non-Controlling Interests over 3 years: stood at $15.8 million in 2021, then soared by 827.4% to $146.2 million in 2022, then sank by 79.58% to $29.8 million in 2023.
• The last three Income from Non-Controlling Interests figures came in at $29.8 million (Q1 2023), $146.2 million (Q4 2022), and -$24.8 million (Q3 2022), per Business Quant data.